The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis
NCT ID: NCT04424706
Last Updated: 2020-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
180 participants
OBSERVATIONAL
2020-06-30
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis
NCT04787770
Glycation of apoA-I and Diabetic Atherogenesis
NCT05659043
Anti-inflammatory Status in DM2 Treated Patients
NCT04392557
Atherothrombosis Markers in Diabetics
NCT02898467
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
NCT03362112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal people
No diabetes and atherosclerosis
people without type 2 diabetes or atherosclerosis
normal people without type 2 diabetes or atherosclerosis
type 2 diabetes mellitus without atherosclerosis
Newly diagnosed type 2 diabetes without atherosclerosis
diagnosed as type 2 diabetes without atherosclerosis
patients diagnosed as type 2 diabetes without atherosclerosis
type 2 diabetes mellitus with atherosclerosis
Newly diagnosed type 2 diabetes with atherosclerosis
diagnosed as type 2 diabetes with atherosclerosis
patients diagnosed as type 2 diabetes with atherosclerosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnosed as type 2 diabetes without atherosclerosis
patients diagnosed as type 2 diabetes without atherosclerosis
diagnosed as type 2 diabetes with atherosclerosis
patients diagnosed as type 2 diabetes with atherosclerosis
people without type 2 diabetes or atherosclerosis
normal people without type 2 diabetes or atherosclerosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic criteria, have not used any drugs.
* The patients have completed carotid ultrasound during hospitalization.
Exclusion Criteria
* impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.
* drug abuse and alcohol dependence in the past 5 years.
* systemic hormone therapy was used in the last three months.
* patients with infection and stress within 4 weeks.
* any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Majianhua
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Majianhua
Head of Department of Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianhua Ma, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Liu B, Su L, Loo SJ, Gao Y, Khin E, Kong X, Dalan R, Su X, Lee KO, Ma J, Ye L. Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes. Front Endocrinol (Lausanne). 2024 Apr 10;15:1369369. doi: 10.3389/fendo.2024.1369369. eCollection 2024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20200320-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.